Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes

Cell(2023)10.1016/j.cell.2023.02.021Source: DataRank Database

Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes is a research paper published in Cell (2023). On theSindex it has a DataRank of 4.9. It has been cited 421 times, with 100 citing works in its 1-hop citation network.

N/A

4.9DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access421 citations · 100 citing works in its network

Download PDF

Cite:

Linked data & code

geo nct

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT03708224

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (14 grants)Impact (FWCI 50.94)OA: hybridTopics (38)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 18%Citation Network 82%

Base Score Contribution

0.907

From this paper's citation signal

Citation Network Contribution

4.0

From 100 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 100 citers.

Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial
The Lancet Oncology2024214 citations26 referencesContributes 0.207
Reduced-Volume Irradiation of Uninvolved Neck in Patients With Nasopharyngeal Cancer: Updated Results From an Open-Label, Noninferiority, Multicenter, Randomized Phase III Trial
Journal of Clinical Oncology202418 citations15 referencesContributes 0.196
Recent highlights of cancer immunotherapy
Holistic Integrative Oncology202325 citations18 referencesContributes 0.181
Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial
The Lancet2023230 citations32 referencesContributes 0.170
Total-Body Dynamic Imaging and Kinetic Modeling of [18F]F-AraG in Healthy Individuals and a Non–Small Cell Lung Cancer Patient Undergoing Anti–PD-1 Immunotherapy
Journal of Nuclear Medicine202417 citations21 referencesContributes 0.138

Authors (23)

Trine Line Hauge Okholm ORCID,Kyle B. Jones ORCID,Elizabeth McCarthy ORCID,Candace C. Liu ORCID,Jacqueline L. Yee ORCID

Live enrichment

PubMed:36931243 PMC:PMC10348701 OpenAlex:https://openalex.org/W4327575929

Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco

Grant: S10 OD025187

Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco

Grant: S10 OD018040

Carlsberg Foundation

Grant: CF19-0493

Improving personalized cancer immunotherapy vaccines by computationally optimizing neoantigen selection

National Institutes of Health

Grant: R01 DE032033

National Institutes of Health

Grant: DP5 OD023056

National Institute of Dental and Craniofacial Research

Grant: K23DE029239

NCI NIH HHS

Grant: R35 CA253175

NIAID NIH HHS

Grant: T32 AI007334

Carlsberg Foundation

Grant: unidentified

unidentified

University of California San Francisco

Genentech Inc

Cancer Research Institute

National Science Foundation

Roche

FWCI

50.94

Citation Percentile

1.0%

Citation Trend

2023

2024

2025

2026

hybridLicense: cc-by

journalhttps://doi.org/10.1016/j.cell.2023.02.021

publisherhttps://doi.org/10.1016/j.cell.2023.02.021

publisherhttps://api.elsevier.com/content/article/PII:S0092867423001642?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0092867423001642?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/36931243

Fields of Study

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesImmune Cell Function and Interaction03 medical and health sciences0302 clinical medicine

MeSH Terms

AnimalsHumansImmunotherapyLymph NodesNeoplasmsCD8-Positive T-LymphocytesMiceTumor Microenvironment

Keywords

BiologyLymphImmunotherapyCancerCancer immunotherapyCD8Cytotoxic T cellCancer researchImmunologyPathologyImmune systemGeneticsMedicineLymph nodesImmune Checkpoint BlockadeCd8(+) T CellsT Cell Exhaustion610CD8-Positive T-LymphocytesMiceNeoplasms616Tumor MicroenvironmentHumansAnimals

Sustainable Development Goals

SDG 0: Good health and well-being